Clinical trials: Enoxaparin, completed
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Acute Coronary Syndrome
Enoxamed Study in the Treatment of Acute Coronary Syndromes
Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin.
- Trial name
- ENOXAMED (NCT02152423)
- Testing
- LOVENOX, ENOXAMED
- Where
- Tunisia
- Volunteers
- 50 people
- Sponsor
- University of Monastir
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Safety Issues, Effect of Drug
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients
The aim of this study is evaluating safety and effectiveness of Ovine Enoxaparin Sodium in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients
- Trial name
- NCT06114641
- Testing
- Enoxaparin sodium injection
- Where
- 3 sites in Indonesia
- Volunteers
- 220 people
- Sponsor
- PT Bio Farma
Venous Thromboembolism, Pulmonary Embolism
: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in postoperative CABG patients, drug is administered either as a continuous intravenous infusion (CIV) or subcutaneous bolus (SCB) once per 72h.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis
- Trial name
- NCT02474212
- Testing
- Enoxaparin
- Where
- Finland
- Volunteers
- 85 people
- Sponsor
- Tampere University Hospital
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
COVID, Coronavirus Infection
A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
Coagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death.
- Conditions
- COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome, Thromboembolism, Venous
- Trial name
- RAPID-BRAZIL (NCT04444700)
- Testing
- Therapeutic anticoagulation
- Where
- Brazil
- Volunteers
- 465 people
- Sponsor
- University of Sao Paulo General Hospital
Venous Thrombosis
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without…
- Trial name
- NCT00440193
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
- Where
- 324 sites in United States, Australia and 32 more
- Volunteers
- 3,449 people
- Sponsor
- Bayer
COVID-19, Venous Thromboembolism
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
Study purpose was to study the safety and efficacy of Dimolegin - DD217 as a drug for prevention of thrombotic complications compared to Clexane (enoxaparin sodium) - the standard therapy currently prescribed to patients…
- Trial name
- NCT05185804
- Testing
- Dimolegin, Clexane
- Where
- 6 sites in Russia
- Volunteers
- 399 people
- Sponsor
- PharmaDiall Ltd.
Pelvic Fractures, Acetabular Fractures
Incidence of Venous Thromboembolism in Patients With Pelvic and Acetabular Fractures (PAF)
The goal of this observational study is to investigate the incidence of venous thromboembolism (VTE) in patients with pelvic and acetabular fractures (PAF).
- Conditions
- Pelvic Fractures, Acetabular Fractures, Pelvic Trauma, Venous Thromboembolic Event
- Trial name
- PAF-VTE (NCT07165587)
- Testing
- Bilateral duplex ultrasonography
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu
Liver Cirrhosis, Portal Vein Thrombosis
Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis
This was a prospective, open-label, pilot interventional clinical study conducted on Egyptian patients with liver cirrhosis complicated by portal vein thrombosis (PVT) who were indicated for anticoagulation therapy.
- Trial name
- NCT07571460
- Testing
- Warfarin 3 mg, Warfarin 2 mg
- Where
- Egypt
- Volunteers
- 21 people
- Sponsor
- Kafrelsheikh University
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Venous Thromboembolic Disease, Deep Vein Thrombosis
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of…
- Conditions
- Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT01729559
- Testing
- 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Scripps Health
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
COVID 19
Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19
Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19.
- Trial name
- NCT06585319
- Testing
- Collagen-polyvinylpyrrolidone, Pirfenidone 1200 mg
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico
Venous Thromboembolism
anti10a Levels in Women Treated With LMWH in the Postpartum Period
The aim of this study is to compare between anti-10a levels in postpartum women receiving different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's weight and the second group receiving 1mg/kg to a…
- Trial name
- NCT02856295
- Testing
- clexane (LMWH)
- Where
- Israel
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Venous Thrombosis
Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
Enoxaparin is a type of low molecular weight heparin (LMWH), or anticoagulant, used to prevent and treat blood clots. Formation of blood clots, or venous thromboemboli (VTE) in pregnancy can have dangerous and even…
- Trial name
- NCT00878826
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Venous Thromboembolism
Low Molecular Weight hEparin vs. Aspirin Post-partum
This is single centre pilot, randomized controlled trial assessing postpartum prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin compared to standard of care of prophylactic LMWH for 6 weeks at…
- Trial name
- LEAP (NCT05058924)
- Testing
- Prophylactic low molecular weight heparin, Low molecular weight heparin and low-dose aspirin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Mount Sinai Hospital, Canada
Venous Thromboembolism
Once Weekly Subcutaneous Ports for the Administration of Anticoagulants
The purpose of this study is to ascertain whether subcutaneous ports are an effective and reliable way to administer the low molecular weight heparin (LMWH) enoxaparin to patients for the prevention or treatment of venous…
- Trial name
- NCT00774748
- Testing
- Insuflon
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill